Research News
View articles by month and year
-
Herceptin Before Surgery Offers Benefits
Herceptin given in combination with chemotherapy BEFORE surgery for HER2-positive locally advanced breast cancer has been shown to improve survival without the breast cancer coming back.
-
Experimental HER2 Vaccine Shows Promise
A very early study done in mice shows promise for a vaccine against HER2-positive cancer cells.
-
If Cancer Stops Responding to Herceptin, It May Have Switched from HER2-Positive to HER2-Negative
A new study suggests that about one-third of HER-positive breast cancers that stop responding or don't respond completely to Herceptin do so because the cancers change from HER2-positive to HER2-negative during treatment.
-
Malignant Stem Cells Seem to Make HER2-Positive Cancers Grow
HER2-positive breast cancers seem to have a large number of abnormal stem cells, which make the cancers grow and spread.
-
Adding Tykerb to Herceptin Helps if Metastatic Breast Cancer Grows
Women diagnosed with HER2-positive metastatic breast cancer that either came back or progressed while getting Herceptin (chemical name: tastuzumab) benefited from adding Tykerb (chemical name: lapatanib) to the treatment plan instead of switching from Herceptin to Tykerb.
-
Herceptin with Dose-Dense Chemo Reduces Risk of Heart Problems
A small study has found that when Herceptin (chemical name: trastuzumab) was given in combination with dose-dense chemotherapy, the risk of heart problems from Herceptin was lower than when Herceptin was given with a routine schedule of chemotherapy.
-
New Study Compares Tykerb and Herceptin
A new clinical trial will try to find out whether using Herceptin (chemical name: trastuzumab) alone, Tykerb (chemical name: lapatinib) alone, or both medicines together is better for women diagnosed with stage I or stage II HER2-positive breast cancer.
-
Inflammatory HER2-Positive Breast Cancer Responds to Herceptin
Inflammatory breast cancers that are HER2-positive are more likely to respond to Herceptin plus chemotherapy than chemotherapy alone.
-
Herceptin Approved in Europe to Treat Breast Cancer
Herceptin plus hormonal therapy for advanced breast cancer is approved in Europe.
-
Herceptin-Avastin Combo Shows Promise
Herceptin combined with Avastin may have benefits for women with HER2-positive, advanced breast cancer.
